Production (Stage)
Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 4.54M | 3.95M | 2.39M | 3.56M | 4.41M |
| Gross Profit | -4.54M | -3.95M | -2.39M | -3.56M | -4.41M |
| SG&A Expenses | 1.94M | 1.63M | 1.32M | 1.32M | 1.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.48M | 5.58M | 3.71M | 4.88M | 6.13M |
| Operating Income | -6.48M | -5.58M | -3.71M | -4.88M | -6.13M |
| Income Before Tax | -6.08M | -4.36M | -6.63M | -4.41M | -5.13M |
| Income Tax Expenses | 63.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.14M | -4.36M | -6.63M | -4.41M | -5.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.14M | -4.36M | -6.63M | -4.41M | -5.13M |
| EBIT | -6.48M | -5.58M | -3.71M | -4.88M | -6.13M |
| EBITDA | -6.48M | -5.57M | -3.71M | -4.88M | -6.13M |
| EPS Basic | -0.04 | -0.04 | -0.06 | -0.04 | -0.05 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| EPS Diluted | -0.04 | -0.04 | -0.06 | -0.04 | -0.05 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | 165.82M | 120.50M | 113.03M | 112.80M | 112.79M |
| Average Diluted Shares Outstanding | 165.82M | 120.50M | 113.03M | 112.80M | 112.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |